Procoagulant Effects of Hyperglycemia After Acute Stroke: A Pilot Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00373269|
Recruitment Status : Completed
First Posted : September 8, 2006
Results First Posted : January 4, 2017
Last Update Posted : February 27, 2017
|Condition or disease|
|Ischemic Stroke Hyperglycemia|
The purpose of this study is to examine the relationships between diabetes mellitus, hyperglycemia,whole blood tissue factor procoagulant activity (TF-PCA) and plasma factorVIIa (FVIIa) in ten patients with type 2 diabetes mellitus and 11 non-diabetic patients at baseline and 6, 12, 24, and 48 hours (h) after presentation for acute stroke.
Patients presenting to the Emergency Department with ongoing stroke symptoms and neurologic deficit less than 24 hours (h) duration were screened for inclusion into the study. Stroke patients were grouped in terms of diabetes status as determined by past medical history. Stroke diagnosis was confirmed with brain magnetic resonance imaging (MRI). Clinical care, including the acute management ofstroke and hyperglycemia, was done at the discretion of the Neurology service not involved in the study.
|Study Type :||Observational|
|Actual Enrollment :||21 participants|
|Official Title:||Procoagulant Effects of Hyperglycemia After Acute Stroke: A Pilot Study|
|Study Start Date :||October 2001|
|Actual Primary Completion Date :||November 2005|
|Actual Study Completion Date :||November 2005|
Subjects with acute stroke, hyperglycemia and history of diabetes.
Subjects with acute stroke and normal blood glucose.
- FVIIa [ Time Frame: Baseline ]FVIIa levels were compared between the normoglycemic and hyperglycemic subjects.
- TF-PCA [ Time Frame: Baseline ]TF-PCA levels compared between normoglycemic and hyperglycemic subjects.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00373269
|Principal Investigator:||Nina T Gentile, MD||Temple University|